Physician profile
Stephen Gregory Fedec
NPI 1629048632
$1,281.93
in general payments reported to CMS, 2019-2025
15 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $91.71 · 2021: $53.37 · 2022: $237 · 2024: $58.14 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $209.47 | 2019-2025 | |
| Cms Imaging, INC. | $202.57 | 2022 | |
| Janssen Pharmaceuticals, INC | $160.60 | 2019-2022 | |
| Abbott Laboratories | $158.00 | 2019-2025 | Pressurewire, Xience Skypoint |
| Amgen INC. | $129.28 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $97.65 | 2019 | |
| Abiomed | $80.04 | 2019 | |
| Pfizer INC. | $49.01 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $45.84 | 2019-2025 | Eliquis |
| Fujifilm Healthcare Americas Corporation | $38.56 | 2021 | |
| Biotronik INC. | $37.16 | 2020-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.60 | 2019-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.35 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.45 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Fedec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.